Emerging players in prostate cancer: long non-coding RNAs.

Recent observations of novel long non-coding RNAs (lncRNAs) have considerably altered our understanding of cell biology. The role of lncRNAs as tumor suppressors or oncogenes has been extensively studied. Over-expression of oncogenic lncRNAs promotes tumor-cell proliferation and metastasis through chromatin looping and distal engagement with the androgen receptor, anti-sense gene regulation, alternative splicing, and impeding DNA repair. Prostate cancer is the most common type of cancer and frequent cause of cancer-related mortality in men worldwide. Unraveling the molecular and biological processes that contribute to prostate cancer development and progression is a challenging task. In prostate cancer, aberrant expression of lncRNAs has been associated with disease progression. In this review, we highlight the emerging impact of lncRNAs in prostate cancer research, with a particular focus on the mechanisms and functions of lncRNAs. Increased research on lncRNAs will lead to a greater understanding of prostate cancercinogenesis and progression and may lead to novel clinical applications. LncRNAs have great potential to become new biomarkers for detection, prognostication and prediction in prostate cancer.

[1]  J. Burnett,et al.  The role of antisense long noncoding RNA in small RNA-triggered gene activation , 2014, RNA.

[2]  Y. Kondo.  Targeting histone methyltransferase EZH2 as cancer treatment. , 2014, Journal of biochemistry.

[3]  G. Chrousos,et al.  Noncoding RNA Gas5 Is a Growth Arrest– and Starvation-Associated Repressor of the Glucocorticoid Receptor , 2010, Science Signaling.

[4]  M. Rosenfeld,et al.  LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs , 2013, Nature.

[5]  W. Lam,et al.  Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer , 2014, Oncotarget.

[6]  R. Kurokawa.  Long noncoding RNA as a regulator for transcription. , 2011, Progress in molecular and subcellular biology.

[7]  J. Hou,et al.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.

[8]  C. Glass,et al.  Enhancer RNAs and regulated transcriptional programs. , 2014, Trends in biochemical sciences.

[9]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[10]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Largaespada,et al.  PVT1 dependence in cancer with MYC copy-number increase , 2014, Nature.

[12]  S. Lenk,et al.  TP53 gene mutations in prostate cancer progression. , 2010, Anticancer research.

[13]  C. Ponting,et al.  Predicting long non-coding RNAs using RNA sequencing. , 2013, Methods.

[14]  Emily A. Vucic,et al.  Human Cancer Long Non-Coding RNA Transcriptomes , 2011, PloS one.

[15]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[16]  Yair Lotan,et al.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Chuanliang Xu,et al.  The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. , 2013, Urologic oncology.

[18]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[19]  Wei Li,et al.  Histone modifications and chromatin organization in prostate cancer. , 2010, Epigenomics.

[20]  Xiang Du,et al.  The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine , 2013, Modern Pathology.

[21]  D. Venzon,et al.  Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. , 2012, The oncologist.

[22]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[23]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[24]  Lin Yang,et al.  Long noncoding RNAs: fresh perspectives into the RNA world. , 2014, Trends in biochemical sciences.

[25]  K. Pienta,et al.  Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. , 2012, Cancer research.

[26]  P. Pandolfi,et al.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.

[27]  Igor Jurisica,et al.  The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. , 2006, Cancer research.

[28]  S. Koschmieder,et al.  The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Anna L. Walsh,et al.  Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? , 2014, Trends in molecular medicine.

[30]  H. Soares,et al.  Non-Coding RNAs: Multi-Tasking Molecules in the Cell , 2013, International journal of molecular sciences.

[31]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[32]  A. Bhan,et al.  Long Noncoding RNAs: Emerging Stars in Gene Regulation, Epigenetics and Human Disease , 2014, ChemMedChem.

[33]  J. Trapman,et al.  ETS fusion genes in prostate cancer. , 2014, Endocrine-related cancer.

[34]  Feng Zhang,et al.  Enhancer Activation Requires trans-Recruitment of a Mega Transcription Factor Complex , 2014, Cell.

[35]  S. Assinder,et al.  Does TGF-β induced formation of actin stress fibres reinforce Smad dependent TGF-β signalling in the prostate? , 2011, Medical hypotheses.

[36]  P. Sharp,et al.  LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. , 2014, Molecular cell.

[37]  Ji-Joon Song,et al.  The coded functions of noncoding RNAs for gene regulation , 2011, Molecules and cells.

[38]  M. Moore,et al.  Genomic Rearrangements of PTEN in Prostate Cancer , 2013, Front. Oncol..

[39]  J. Hou,et al.  Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. , 2013, European journal of cancer.

[40]  P. Nelson,et al.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. , 2010, The Journal of clinical investigation.

[41]  Jing Zhao,et al.  Activation of p53 by MEG3 Non-coding RNA* , 2007, Journal of Biological Chemistry.

[42]  S. Dhanasekaran,et al.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex , 2013, Nature Genetics.

[43]  Y. Bignon,et al.  Epigenetic modifications in prostate cancer. , 2014, Epigenomics.

[44]  A. Chinnaiyan,et al.  The lncRNAs PCGEM 1 and PRNCR 1 are not implicated in castration resistant prostate cancer , 2014 .

[45]  Zhenhua Li,et al.  ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival. , 2011, Urology.